Low-Carb Breakfast May Improve All-Day Glucose Control in T2DM
TUESDAY, April 16, 2019 -- A very low-carbohydrate, high-fat breakfast may be a practical and easy way for patients with type 2 diabetes to lower their overall exposure to postprandial hyperglycemia and improve glycemic variability, according to a study published online April 9 in The American Journal of Clinical Nutrition.
Courtney R. Chang, from the University of British Columbia in Vancouver, Canada, and colleagues assessed the impact of breakfast diet on daily postprandial hyperglycemia using continuous glucose monitoring. Adults with physician-diagnosed type 2 diabetes (23 participants; mean age, 59 years) completed two 24-hour feeding interventions: a very low-carbohydrate, high-fat breakfast (LCBF) and a breakfast with a dietary guidelines-recommended nutrient profile (GLBF). The same lunch and dinner were provided to both groups.
The researchers found that the LCBF significantly reduced postprandial hyperglycemia after breakfast and did not adversely affect glycemia after lunch or dinner. Compared with the GLBF, overall postprandial hyperglycemia and glycemic variability were reduced with the LCBF (24-hour incremental area under the glucose curve, −173 ± 361 mmol/L; mean amplitude of glycemic excursions, −0.4 ± 0.8 mmol/L). Compared with the GLBF, premeal hunger was lower before dinner with the LCBF.
"The results of our study suggest potential benefits of altering macronutrient distribution throughout the day so that carbohydrates are restricted at breakfast with a balanced lunch and dinner rather than consuming an even distribution and moderate amount of carbohydrates throughout the day," a coauthor said in a statement.
© 2020 HealthDay. All rights reserved.
Posted: April 2019
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.